Aurinia Pharmaceuticals (AUPH)

Aurinia’s strategy combines commercial execution in nephrology and rheumatology with targeted research in immune-mediated disease. LUPKYNIS gives the company a differentiated position because it is an oral therapy specifically approved for active lupus nephritis, rather than a broad immunosuppressive medicine used off label. The product is used alongside background immunosuppressive treatment, reflecting the multi-drug approach often required in this disease area.

Beyond its marketed product, Aurinia is developing aritinercept, an investigational dual inhibitor of BAFF and APRIL. These immune-signaling pathways are involved in B-cell activity and autoantibody production, making them relevant to several autoimmune disorders. The candidate reflects the company’s interest in mechanisms that may address the biological drivers of chronic immune diseases.

For investors, Aurinia represents a specialist biotech company whose value is tied to LUPKYNIS uptake, reimbursement, physician adoption, competitive dynamics in lupus nephritis, and the progress of its pipeline. Its business sits at the intersection of rare autoimmune disease, kidney care, and targeted immunology.